According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded shares of Derma Sciences from a sell rating to a hold rating in a research note on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $7.35.
Derma Sciences (NASDAQ:DSCI) opened at 4.58 on Tuesday. Derma Sciences has a 12 month low of $2.85 and a 12 month high of $5.99. The company has a 50-day moving average of $4.71 and a 200 day moving average of $4.19. The company’s market cap is $129.64 million.
Derma Sciences (NASDAQ:DSCI) last issued its earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.16. The firm had revenue of $22.20 million for the quarter, compared to the consensus estimate of $22.40 million. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. On average, equities analysts forecast that Derma Sciences will post ($0.04) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. boosted its position in Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares during the last quarter. Vanguard Group Inc. boosted its position in Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock valued at $207,000 after buying an additional 7,086 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in Derma Sciences during the second quarter valued at $202,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock valued at $364,000 after buying an additional 73,911 shares during the last quarter. 62.44% of the stock is owned by hedge funds and other institutional investors.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.